US6413536B1
(en)
|
1995-06-07 |
2002-07-02 |
Southern Biosystems, Inc. |
High viscosity liquid controlled delivery system and medical or surgical device
|
US7833543B2
(en)
*
|
1995-06-07 |
2010-11-16 |
Durect Corporation |
High viscosity liquid controlled delivery system and medical or surgical device
|
GB9616237D0
(en)
|
1996-08-01 |
1996-09-11 |
Norton Healthcare Ltd |
Aerosol formulations
|
US6126919A
(en)
*
|
1997-02-07 |
2000-10-03 |
3M Innovative Properties Company |
Biocompatible compounds for pharmaceutical drug delivery systems
|
US6598603B1
(en)
*
|
1997-12-31 |
2003-07-29 |
Astra Aktiebolag |
Method for treating respiratory diseases
|
SE9804001D0
(sv)
*
|
1998-11-23 |
1998-11-23 |
Astra Ab |
New process
|
DZ2947A1
(fr)
|
1998-11-25 |
2004-03-15 |
Chiesi Farma Spa |
Inhalateur à compteur de dose sous pression.
|
IT1303788B1
(it)
*
|
1998-11-25 |
2001-02-23 |
Chiesi Farma Spa |
Formulazioni di aerosol medicinali.
|
US6319521B1
(en)
*
|
1999-02-10 |
2001-11-20 |
University Technology Corporation |
Microparticles of lactide-co-glycolide copolymers and methods of making and using the same
|
JP4548623B2
(ja)
*
|
1999-02-24 |
2010-09-22 |
多木化学株式会社 |
生体材料
|
HUP0201626A3
(en)
*
|
1999-06-04 |
2004-05-28 |
Alza Corp Mountain View |
Implantable gel compositions and method of manufacture
|
US6315985B1
(en)
*
|
1999-06-18 |
2001-11-13 |
3M Innovative Properties Company |
C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
|
IT1313553B1
(it)
|
1999-07-23 |
2002-09-09 |
Chiesi Farma Spa |
Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
|
CA2393776C
(en)
*
|
1999-12-15 |
2009-02-10 |
Sulzer Orthopedics Ltd. |
Preparation for repairing cartilage defects or cartilage/bone defects in human or animal joints
|
US6651655B1
(en)
*
|
2000-01-18 |
2003-11-25 |
Quadrant Technologies Limited |
Inhaled vaccines
|
IT1317846B1
(it)
|
2000-02-22 |
2003-07-15 |
Chiesi Farma Spa |
Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
|
DZ3358A1
(fr)
|
2000-05-22 |
2001-11-29 |
Chiesi Farma Spa |
Formulations en solution pharmaceutiques pour inhalateurs-doseurs sous pression
|
AU2001281746C1
(en)
|
2000-07-31 |
2010-09-09 |
ISTITUTO GENTILI S.r.l. |
Fentanyl composition for nasal administration
|
US6777399B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
GB0019172D0
(en)
|
2000-08-05 |
2000-09-27 |
Glaxo Group Ltd |
Novel compounds
|
US6759398B2
(en)
|
2000-08-05 |
2004-07-06 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative
|
US6750210B2
(en)
|
2000-08-05 |
2004-06-15 |
Smithkline Beecham Corporation |
Formulation containing novel anti-inflammatory androstane derivative
|
US6787532B2
(en)
|
2000-08-05 |
2004-09-07 |
Smithkline Beecham Corporation |
Formulation containing anti-inflammatory androstane derivatives
|
US6777400B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
US6858593B2
(en)
|
2000-08-05 |
2005-02-22 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
DE10058829B4
(de)
*
|
2000-11-27 |
2004-08-26 |
3M Espe Ag |
Verwendung von Polysäuren mit enger Molmassenverteilung
|
UA77656C2
(en)
|
2001-04-07 |
2007-01-15 |
Glaxo Group Ltd |
S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
|
US20030055026A1
(en)
|
2001-04-17 |
2003-03-20 |
Dey L.P. |
Formoterol/steroid bronchodilating compositions and methods of use thereof
|
US6667344B2
(en)
|
2001-04-17 |
2003-12-23 |
Dey, L.P. |
Bronchodilating compositions and methods
|
WO2002092154A1
(en)
|
2001-04-26 |
2002-11-21 |
New England Pharmaceuticals, Inc. |
Metered dose delivery device for liquid and powder agents
|
US20030051728A1
(en)
|
2001-06-05 |
2003-03-20 |
Lloyd Peter M. |
Method and device for delivering a physiologically active compound
|
US7645442B2
(en)
|
2001-05-24 |
2010-01-12 |
Alexza Pharmaceuticals, Inc. |
Rapid-heating drug delivery article and method of use
|
US20070122353A1
(en)
|
2001-05-24 |
2007-05-31 |
Hale Ron L |
Drug condensation aerosols and kits
|
US7458374B2
(en)
|
2002-05-13 |
2008-12-02 |
Alexza Pharmaceuticals, Inc. |
Method and apparatus for vaporizing a compound
|
DK1273292T3
(da)
|
2001-07-02 |
2004-10-04 |
Chiesi Farma Spa |
Optimeret tobramycinformulering til aerosoldannelse
|
DE10137102A1
(de)
*
|
2001-07-30 |
2003-02-27 |
Deutsches Krebsforsch |
Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
|
DE10141650C1
(de)
|
2001-08-24 |
2002-11-28 |
Lohmann Therapie Syst Lts |
Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
|
US6592899B2
(en)
|
2001-10-03 |
2003-07-15 |
Macromed Incorporated |
PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
|
WO2003037317A1
(en)
*
|
2001-10-26 |
2003-05-08 |
Dey, L.P. |
Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
|
DE60231428D1
(de)
*
|
2001-12-21 |
2009-04-16 |
3M Innovative Properties Co |
Medizinische aerosolzusammensetzungen mit einem funktionalisierten polyethylenglykol-hilfsstoff
|
US20030147814A1
(en)
*
|
2001-12-21 |
2003-08-07 |
3M Innovative Properties Company |
Medicinal aerosol formulations comprising ion pair complexes
|
ATE406152T1
(de)
*
|
2001-12-21 |
2008-09-15 |
3M Innovative Properties Co |
Medizinische aerosolzusammensetzungen mit einer eine amid- und/oder estergruppe enthaltenden exzipientenverbindung
|
EP1340503A1
(en)
*
|
2002-03-01 |
2003-09-03 |
CHIESI FARMACEUTICI S.p.A. |
Solution aerosol formulation containing esters of 3, 17-dihydroxy oestratriene derivates for pulmonary delivery
|
JP2005523905A
(ja)
|
2002-03-01 |
2005-08-11 |
キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ |
ホルモテロール(formoterol)超微細調合物
|
GB2389530B
(en)
|
2002-06-14 |
2007-01-10 |
Cipla Ltd |
Pharmaceutical compositions
|
US20040001889A1
(en)
|
2002-06-25 |
2004-01-01 |
Guohua Chen |
Short duration depot formulations
|
US7947742B2
(en)
*
|
2002-06-28 |
2011-05-24 |
Civitas Therapeutics, Inc. |
Inhalable epinephrine
|
US20040023935A1
(en)
*
|
2002-08-02 |
2004-02-05 |
Dey, L.P. |
Inhalation compositions, methods of use thereof, and process for preparation of same
|
UA84276C2
(uk)
*
|
2002-08-27 |
2008-10-10 |
Хіроші Терада |
Лікарський засіб проти туберкульозу
|
US6966990B2
(en)
|
2002-10-11 |
2005-11-22 |
Ferro Corporation |
Composite particles and method for preparing
|
US20040105818A1
(en)
|
2002-11-26 |
2004-06-03 |
Alexza Molecular Delivery Corporation |
Diuretic aerosols and methods of making and using them
|
US7913688B2
(en)
|
2002-11-27 |
2011-03-29 |
Alexza Pharmaceuticals, Inc. |
Inhalation device for producing a drug aerosol
|
US20040109826A1
(en)
*
|
2002-12-06 |
2004-06-10 |
Dey, L.P. |
Stabilized albuterol compositions and method of preparation thereof
|
WO2004054542A2
(en)
|
2002-12-13 |
2004-07-01 |
Durect Corporation |
Oral drug delivery system comprising high viscosity liquid carrier materials
|
GB0300531D0
(en)
|
2003-01-10 |
2003-02-12 |
West Pharm Serv Drug Res Ltd |
Pharmaceutical compositions
|
US6931888B2
(en)
*
|
2003-02-07 |
2005-08-23 |
Ferro Corporation |
Lyophilization method and apparatus for producing particles
|
US7083748B2
(en)
*
|
2003-02-07 |
2006-08-01 |
Ferro Corporation |
Method and apparatus for continuous particle production using supercritical fluid
|
KR20050105490A
(ko)
*
|
2003-02-26 |
2005-11-04 |
오츠카 세이야쿠 가부시키가이샤 |
경폐 투여용 서방성 제제학적 조성물
|
WO2004087777A2
(en)
*
|
2003-03-28 |
2004-10-14 |
Carnegie Mellon University |
Degradable polymers
|
US20040265351A1
(en)
*
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
FR2854071B1
(fr)
*
|
2003-04-25 |
2009-01-30 |
Ethypharm Sa |
Procede de dispersion de substances hydrosolubles ou hydrophiles dans un fluide a pression supercritique
|
US7879357B2
(en)
*
|
2003-04-28 |
2011-02-01 |
Bayer Schering Pharma Ag |
Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
|
US20060008531A1
(en)
*
|
2003-05-08 |
2006-01-12 |
Ferro Corporation |
Method for producing solid-lipid composite drug particles
|
CA2526475A1
(en)
|
2003-05-21 |
2004-12-02 |
Alexza Pharmaceuticals, Inc. |
Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
|
TWI359675B
(en)
*
|
2003-07-10 |
2012-03-11 |
Dey L P |
Bronchodilating β-agonist compositions
|
EP1699847B1
(en)
*
|
2003-12-30 |
2011-04-13 |
3M Innovative Properties Company |
Method for the preparation of medicinal compositions
|
US20050271597A1
(en)
*
|
2004-02-13 |
2005-12-08 |
Keith Alec D |
Prostate hypertrophy treatment composition and method
|
EP1595531A1
(en)
|
2004-05-13 |
2005-11-16 |
CHIESI FARMACEUTICI S.p.A. |
Stable pharmaceutical solution formulations for pressurized metered dose inhalers
|
JP5171248B2
(ja)
|
2004-03-05 |
2013-03-27 |
カーネギー−メロン ユニバーシティ |
原子移動ラジカル重合法
|
EP1732527A2
(en)
*
|
2004-03-17 |
2006-12-20 |
Mpex Pharmaceuticals, Inc. |
Use and administration of bacterial efflux pump inhibitors
|
US7994225B2
(en)
*
|
2004-03-17 |
2011-08-09 |
Rempex Pharmaceuticals, Inc. |
Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
|
US7540286B2
(en)
|
2004-06-03 |
2009-06-02 |
Alexza Pharmaceuticals, Inc. |
Multiple dose condensation aerosol devices and methods of forming condensation aerosols
|
ES2602273T3
(es)
|
2004-09-17 |
2017-02-20 |
Durect Corporation |
Composición anestésica local prolongada que contiene Saib
|
US7115561B2
(en)
*
|
2004-09-22 |
2006-10-03 |
Patterson James A |
Medicament composition and method of administration
|
MX2007003468A
(es)
*
|
2004-09-24 |
2007-05-18 |
3M Innovative Properties Co |
Formulaciones medicinales en aerosol y metodos de sintesis de los ingredientes para las mismas.
|
MX2007011161A
(es)
*
|
2005-03-14 |
2007-11-13 |
3M Innovative Properties Co |
Compuestos polimericos biocompatibles para formulaciones medicinales.
|
EP1883665B1
(en)
|
2005-04-22 |
2017-10-11 |
Universite De Geneve |
Polylactide compositions and uses thereof
|
US20070027105A1
(en)
|
2005-07-26 |
2007-02-01 |
Alza Corporation |
Peroxide removal from drug delivery vehicle
|
US7919583B2
(en)
*
|
2005-08-08 |
2011-04-05 |
Discovery Genomics, Inc. |
Integration-site directed vector systems
|
US8367734B1
(en)
|
2005-08-11 |
2013-02-05 |
Amphastar Pharmaceuticals Inc. |
Stable epinephrine suspension formulation with high inhalation delivery efficiency
|
WO2007025086A2
(en)
|
2005-08-23 |
2007-03-01 |
Carnegie Mellon University |
Atom transfer radical polymerization in microemulsion and true emulsion polymerization
|
CN101379091B
(zh)
|
2005-08-26 |
2012-05-30 |
卡内基梅隆大学 |
在催化剂再生下的聚合方法
|
US20070196416A1
(en)
|
2006-01-18 |
2007-08-23 |
Quest Pharmaceutical Services |
Pharmaceutical compositions with enhanced stability
|
US20090123391A1
(en)
*
|
2006-03-22 |
2009-05-14 |
3M Innovative Properties Company |
Novel Formulations
|
US7943651B2
(en)
|
2006-04-20 |
2011-05-17 |
Glaxo Group Limited |
Compounds
|
GB0611587D0
(en)
|
2006-06-12 |
2006-07-19 |
Glaxo Group Ltd |
Novel compounds
|
US8580307B2
(en)
*
|
2006-06-22 |
2013-11-12 |
Ethicon, Inc. |
High glass transition temperature absorbable microspheres
|
JP2009545579A
(ja)
|
2006-08-01 |
2009-12-24 |
グラクソ グループ リミテッド |
ピラゾロ[3,4−b]ピリジン化合物、及びpde4阻害薬としてのその使用
|
US20080269347A1
(en)
*
|
2006-09-28 |
2008-10-30 |
Azopharma, Inc. |
Epinephrine formulations
|
US8367051B2
(en)
|
2006-10-09 |
2013-02-05 |
Carnegie Mellon University |
Preparation of functional gel particles with a dual crosslink network
|
PL2117521T3
(pl)
|
2006-11-03 |
2012-11-30 |
Durect Corp |
Transdermalne systemy dostarczania zawierające bupiwakainę
|
US20080216828A1
(en)
|
2007-03-09 |
2008-09-11 |
Alexza Pharmaceuticals, Inc. |
Heating unit for use in a drug delivery device
|
WO2008148000A1
(en)
|
2007-05-23 |
2008-12-04 |
Carnegie Mellon University |
Atom transfer dispersion polymerization
|
WO2009023353A1
(en)
|
2007-05-23 |
2009-02-19 |
Carnegie Mellon University |
Hybrid particle composite structures with reduced scattering
|
WO2008152398A2
(en)
*
|
2007-06-14 |
2008-12-18 |
Cipla Limited |
Formulations for inhalation
|
WO2009052519A2
(en)
*
|
2007-10-19 |
2009-04-23 |
Wayne State University |
Co-polymer stabilizers for hydrofluoroalkane dispersions
|
JP2011503183A
(ja)
*
|
2007-11-13 |
2011-01-27 |
サーモディクス ファーマシューティカルズ, インコーポレイテッド |
薬物送達のプラットホームとしての粘稠なターポリマー
|
WO2009075782A1
(en)
|
2007-12-06 |
2009-06-18 |
Durect Corporation |
Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
|
US7979151B2
(en)
*
|
2007-12-06 |
2011-07-12 |
International Business Machines Corporation |
Run-time dispatch system for enhanced product characterization capability
|
CN101896169B
(zh)
*
|
2007-12-12 |
2012-11-14 |
巴斯夫欧洲公司 |
具有聚合物抗衡离子的活性成分的盐
|
US9308162B2
(en)
*
|
2008-06-03 |
2016-04-12 |
Tolmar Therapeutics, Inc. |
Biocompatible oligomer-polymer compositions
|
US8927617B2
(en)
|
2008-06-30 |
2015-01-06 |
Kimberly-Clark Worldwide, Inc. |
Fragranced water-sensitive film
|
US8759279B2
(en)
*
|
2008-06-30 |
2014-06-24 |
Kimberly-Clark Worldwide, Inc. |
Fragranced biodegradable film
|
WO2010008564A2
(en)
*
|
2008-07-16 |
2010-01-21 |
Recombinetics |
Plaice dna transposon system
|
EP3246030A1
(en)
|
2008-08-11 |
2017-11-22 |
GlaxoSmithKline LLC |
Novel adenine derivatives
|
WO2010018131A1
(en)
|
2008-08-11 |
2010-02-18 |
Smithkline Beecham Corporation |
Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
|
UA103195C2
(uk)
|
2008-08-11 |
2013-09-25 |
Глаксосмитклайн Ллк |
Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
US20100158978A1
(en)
*
|
2008-12-23 |
2010-06-24 |
Peter Markland |
Bioactive spray coating compositions and methods of making and uses thereof
|
US8974808B2
(en)
*
|
2008-12-23 |
2015-03-10 |
Surmodics, Inc. |
Elastic implantable composites and implants comprising same
|
US8951546B2
(en)
|
2008-12-23 |
2015-02-10 |
Surmodics Pharmaceuticals, Inc. |
Flexible implantable composites and implants comprising same
|
US20100168807A1
(en)
*
|
2008-12-23 |
2010-07-01 |
Burton Kevin W |
Bioactive terpolymer compositions and methods of making and using same
|
US9415197B2
(en)
|
2008-12-23 |
2016-08-16 |
Surmodics, Inc. |
Implantable suction cup composites and implants comprising same
|
US9925282B2
(en)
|
2009-01-29 |
2018-03-27 |
The General Hospital Corporation |
Cromolyn derivatives and related methods of imaging and treatment
|
WO2010094643A1
(en)
|
2009-02-17 |
2010-08-26 |
Glaxo Group Limited |
Quinoline derivatives and their uses for rhinitis and urticaria
|
US20120016011A1
(en)
|
2009-03-19 |
2012-01-19 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
JP2012520685A
(ja)
|
2009-03-19 |
2012-09-10 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いたGATA結合タンパク質3(GATA3)遺伝子発現のRNA干渉媒介性阻害
|
US20120035247A1
(en)
|
2009-03-19 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
EA201171144A1
(ru)
|
2009-03-19 |
2012-04-30 |
Мерк Шарп Энд Домэ Корп. |
ОПОСРЕДОВАННОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНА ГОМОЛОГА 1 BTB И CNC, ОСНОВНОГО ФАКТОРА ТРАНСКРИПЦИИ С ЛЕЙЦИНОВОЙ МОЛНИЕЙ 1 (Bach1) С ИСПОЛЬЗОВАНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
|
WO2010111497A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20120022143A1
(en)
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp |
RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
|
GB2481561B
(en)
|
2009-03-27 |
2013-12-11 |
Univ Carnegie Mellon |
Preparation of functional star macromolecules
|
EP2411516A1
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2010111471A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
JP2012521762A
(ja)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いた神経成長因子β鎖(NGFβ)遺伝子発現のRNA干渉媒介性阻害
|
CA2756072A1
(en)
*
|
2009-03-30 |
2010-10-14 |
Cerulean Pharma Inc. |
Polymer-agent conjugates, particles, compositions, and related methods of use
|
WO2010114768A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-epothilone conjugates, particles, compositions, and related methods of use
|
WO2010114770A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-agent conjugates, particles, compositions, and related methods of use
|
US8399436B2
(en)
|
2009-04-24 |
2013-03-19 |
Glaxo Group Limited |
N-pyrazolyl carboxamides as CRAC channel inhibitors
|
JP2012524754A
(ja)
|
2009-04-24 |
2012-10-18 |
グラクソ グループ リミテッド |
Cracチャネル阻害剤としてのピラゾールおよびトリアゾ−ルカルボキサミド
|
DK2501363T3
(en)
|
2009-11-17 |
2015-03-23 |
Cipla Ltd |
inhalable
|
GB0921075D0
(en)
|
2009-12-01 |
2010-01-13 |
Glaxo Group Ltd |
Novel combination of the therapeutic agents
|
US9993441B2
(en)
|
2009-12-30 |
2018-06-12 |
Surmodics, Inc. |
Controlled release matrix barrier structure for subcutaneous medical devices
|
US8703754B2
(en)
|
2010-02-10 |
2014-04-22 |
Glaxosmithkline Llc |
6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8H-purin-8-one maleate
|
US8575340B2
(en)
|
2010-02-10 |
2013-11-05 |
Glaxosmithkline Llc |
Purine derivatives and their pharmaceutical uses
|
EP3330377A1
(en)
|
2010-08-02 |
2018-06-06 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
EP3587574B1
(en)
|
2010-08-17 |
2022-03-16 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
WO2012027467A1
(en)
|
2010-08-26 |
2012-03-01 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2012030822A1
(en)
|
2010-08-30 |
2012-03-08 |
Surmodics Pharmaceuticals, Inc. |
Process for reducing moisture in a biodegradable implant device
|
US9113916B2
(en)
|
2010-08-31 |
2015-08-25 |
Zimmer, Inc. |
Drill bit for osteochondral drilling with guiding element and uses thereof
|
JP5795643B2
(ja)
|
2010-10-21 |
2015-10-14 |
グラクソ グループ リミテッドGlaxo Group Limited |
アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物
|
JP2013544794A
(ja)
|
2010-10-21 |
2013-12-19 |
グラクソ グループ リミテッド |
アレルギー性障害、炎症性障害及び免疫障害に作用するピラゾール化合物
|
EP3327125B1
(en)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
WO2012091965A1
(en)
|
2010-12-17 |
2012-07-05 |
Carnegie Mellon University |
Electrochemically mediated atom transfer radical polymerization
|
CA2838030A1
(en)
|
2011-06-08 |
2012-12-13 |
Glaxo Group Limited |
Combination comprising umeclidinium and a corticosteroid
|
EP2747753B1
(en)
|
2011-08-22 |
2023-03-29 |
Carnegie Mellon University |
Atom transfer radical polymerization under biologically compatible conditions
|
EP2773324A4
(en)
*
|
2011-11-03 |
2015-07-01 |
Prec Dermatology Inc |
STABLE DERMATOLOGICAL AEROSOL FOAMS USING REACTIVE PROPELLERS
|
WO2013126745A2
(en)
|
2012-02-23 |
2013-08-29 |
Carnegie Mellon University |
Ligands designed to provide highly active catalyst complexes
|
KR20140147891A
(ko)
|
2012-04-13 |
2014-12-30 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
응집체 입자
|
WO2013165816A2
(en)
|
2012-05-02 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
CN109846862A
(zh)
|
2012-10-25 |
2019-06-07 |
通用医疗公司 |
治疗阿尔茨海默病及相关疾病的组合疗法
|
US10058530B2
(en)
|
2012-10-25 |
2018-08-28 |
The General Hospital Corporation |
Combination therapies for the treatment of Alzheimer's disease and related disorders
|
EP2928877B1
(en)
|
2012-12-06 |
2020-01-22 |
Merck Sharp & Dohme Corp. |
Disulfide masked prodrug compositions and methods
|
WO2014144975A1
(en)
|
2013-03-15 |
2014-09-18 |
Durect Corporation |
Compositions with a rheological modifier to reduce dissolution variability
|
US10525005B2
(en)
|
2013-05-23 |
2020-01-07 |
The General Hospital Corporation |
Cromolyn compositions and methods thereof
|
MX2015016102A
(es)
|
2013-05-23 |
2016-08-08 |
Aztherapies Inc |
Metodos para la liberacion de cromolina.
|
EP3060205A4
(en)
|
2013-10-22 |
2017-06-28 |
The General Hospital Corporation |
Cromolyn derivatives and related methods of imaging and treatment
|
WO2015088990A1
(en)
|
2013-12-09 |
2015-06-18 |
Durect Corporation |
Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
|
SI3104854T1
(sl)
|
2014-02-10 |
2020-09-30 |
Respivant Sciences Gmbh |
Stabilizatorji mastocitov za zdravljenje pljučnih bolezni
|
CN106456595A
(zh)
|
2014-02-10 |
2017-02-22 |
帕塔拉制药有限责任公司 |
用于***性病症的肥大细胞稳定剂治疗
|
JP6452711B2
(ja)
|
2014-02-20 |
2019-01-16 |
グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited |
ヒトインターフェロンの誘導物質としてのピロロ[3,2]ピリミジン誘導体
|
US9968758B2
(en)
*
|
2014-03-21 |
2018-05-15 |
Boston Scientific Scimed, Inc. |
Devices and methods for treating a lung
|
WO2016067252A1
(en)
|
2014-10-31 |
2016-05-06 |
Glaxosmithkline Intellectual Property Development Limited |
Powder formulation
|
ES2917887T3
(es)
|
2014-11-13 |
2022-07-12 |
Glaxosmithkline Biologicals Sa |
Derivados de adenina que son útiles en el tratamiento de enfermedades alérgicas u otras afecciones inflamatorias
|
US9982070B2
(en)
|
2015-01-12 |
2018-05-29 |
Carnegie Mellon University |
Aqueous ATRP in the presence of an activator regenerator
|
EP3331522A1
(en)
|
2015-08-07 |
2018-06-13 |
Patara Pharma LLC |
Methods for the treatment of mast cell related disorders with mast cell stabilizers
|
US10265296B2
(en)
|
2015-08-07 |
2019-04-23 |
Respivant Sciences Gmbh |
Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
|
GB201516243D0
(en)
|
2015-09-14 |
2015-10-28 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
JP2018535984A
(ja)
|
2015-11-18 |
2018-12-06 |
グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited |
リバビリンの医薬組成物
|
WO2017093933A1
(en)
|
2015-12-03 |
2017-06-08 |
Glaxosmithkline Intellectual Property Development Limited |
Cyclic purine dinucleotides as modulators of sting
|
AR107044A1
(es)
|
2015-12-17 |
2018-03-14 |
Astex Therapeutics Ltd |
Compuesto de quinolin-3-carboxamida, composición farmacéutica que lo comprende y su uso para prepararla
|
AU2017321782B2
(en)
|
2016-08-31 |
2022-03-10 |
The General Hospital Corporation |
Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
|
JP2019528320A
(ja)
|
2016-08-31 |
2019-10-10 |
レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングRespivant Sciences Gmbh |
特発性肺線維症による慢性咳の治療のためのクロモリン組成物
|
CN109803724A
(zh)
|
2016-10-07 |
2019-05-24 |
瑞思皮万特科学有限责任公司 |
用于治疗肺纤维化的色甘酸组合物
|
WO2018132582A1
(en)
|
2017-01-12 |
2018-07-19 |
Carnegie Mellon University |
Surfactant assisted formation of a catalyst complex for emulsion atom transfer radical polymerization processes
|
EP3654946A4
(en)
|
2017-07-20 |
2021-04-21 |
AZTherapies, Inc. |
POWDER FORMULATIONS OF CROMOLYN SODIUM AND IBUPROFEN
|
EP3743041A1
(en)
|
2018-01-26 |
2020-12-02 |
Apidel SA |
New spironolactone formulations and their use
|
AU2019289228A1
(en)
|
2018-06-22 |
2021-01-21 |
Ucl Business Ltd |
Novel compounds
|
CA3105392A1
(en)
|
2018-07-02 |
2020-01-09 |
The General Hospital Corporation |
Powdered formulations of cromolyn sodium and .alpha.-lactose
|
KR20220140711A
(ko)
|
2020-01-13 |
2022-10-18 |
듀렉트 코퍼레이션 |
불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
|